NEW YORK (GenomeWeb News) – Epigenomics today announced that a US Food and Drug Administration panel voted in favor of the company’s Epi proColon colorectal cancer screening test but with concerns.

In a meeting held on Wednesday, the Molecular and Clinical Genetics Panel of FDA's Medical Devices Advisory Committee voted that the benefits of the test outweigh the risk for use in patients "who meet the criteria," Epigenomics said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Helix customers can purchase apps that interpret different aspects of their genome, Technology Review reports.

The New York Times reports that a number of companies and research institutes are pursuing gene therapies.

Salmon with shorter telomeres survive to make the trip back to their river homes, New Scientist reports.

In PLOS this week: vaginal microbiome composition, population patterns of Chagas-carrying Rhodnius ecuadoriensis, and more.